• Something wrong with this record ?

Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial

P. Kelly, R. Lemmens, C. Weimar, C. Walsh, F. Purroy, M. Barber, R. Collins, S. Cronin, A. Czlonkowska, P. Desfontaines, A. De Pauw, NR. Evans, U. Fischer, C. Fonseca, J. Forbes, MD. Hill, D. Jatuzis, J. Kõrv, P. Kraft, C. Kruuse, C. Lynch, D....

. 2024 ; 404 (10448) : 125-133. [pub] 20240607

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial

E-resources Online Full text

NLK ProQuest Central from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest) from 1992-01-04 to 3 months ago
Family Health Database (ProQuest) from 1992-01-04 to 3 months ago
Psychology Database (ProQuest) from 1992-01-04 to 3 months ago
Health Management Database (ProQuest) from 1992-01-04 to 3 months ago
Public Health Database (ProQuest) from 1992-01-04 to 3 months ago

BACKGROUND: Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke. METHODS: We did a randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0·5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible. The primary endpoint was a composite of first fatal or non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation (defined as an admission to an inpatient unit or a visit to an emergency department that resulted in at least a 24 h stay [or a change in calendar date if the hospital admission or discharge times were not available]) for unstable angina. The p value for significance was 0·048 to adjust for two prespecified interim analyses conducted by the data monitoring committee, for which the steering committee and trial investigators remained blinded. The trial was registered at ClinicalTrials.gov (NCT02898610) and is completed. FINDINGS: 3154 patients were randomly assigned between Dec 19, 2016, and Nov 21, 2022, with the last follow-up on Jan 31, 2024. The trial finished before the anticipated number of outcomes was accrued (367 outcomes planned) due to budget constraints attributable to the COVID-19 pandemic. Ten patients withdrew consent for analysis of their data, leaving 3144 patients in the intention-to-treat analysis: 1569 (colchicine and usual care) and 1575 (usual care alone). A primary endpoint occurred in 338 patients, 153 (9·8%) of 1569 patients allocated to colchicine and usual care and 185 (11·7%) of 1575 patients allocated to usual care alone (incidence rates 3·32 vs 3·92 per 100 person-years, hazard ratio 0·84; 95% CI 0·68-1·05, p=0·12). Although no between-group difference in C-reactive protein (CRP) was observed at baseline, patients treated with colchicine had lower CRP at 28 days and at 1, 2, and 3 years (p<0·05 for all timepoints). The rates of serious adverse events were similar in both groups. INTERPRETATION: Although no statistically significant benefit was observed on the primary intention-to-treat analysis, the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials. FUNDING: Health Research Board Ireland, Deutsche Forschungsgemeinschaft (German Research Foundation), and Fonds Wetenschappelijk Onderzoek Vlaanderen (Research Foundation Flanders), Belgium.

AZ Oostende Ostend Belgium

Biomedical Research Institute of Lleida Universitat de Lleida Lleida Spain

Center for Clinical Trials Essen University Hospital Essen Essen Germany

Centre for Clinical Brain Sciences University of Edinburgh Edinburgh UK

Centre of Neurology Institute of Clinical Medicine Faculty of Medicine Vilnius University Vilnius Lithuania

Cork University Hospital Cork Ireland

Department of Clinical Neurosciences and Hotchkiss Brain Institute Cumming School of Medicine University of Calgary and Foothills Medical Centre Calgary AB Canada

Department of Clinical Neurosciences University of Cambridge Cambridge UK

Department of Neurology Amsterdam University Medical Centers Amsterdam Netherlands

Department of Neurology and Department of Geriatric and Stroke Medicine Tallaght University Hospital The Adelaide and Meath Hospital Dublin Ireland incorporating the National Children's Hospital and Academic Unit of Neurology School of Medicine Trinity College Dublin Dublin Ireland

Department of Neurology and Neurosurgery University of Tartu Tartu Estonia

Department of Neurology Herlev and Gentofte Hospital and Department of Brain and Spinal Cord Injury Rigshospitalet Hospital Copenhagen University Hospital Copenhagen Denmark

Department of Neurology University Hospital Bern and University of Bern Bern Switzerland

Department of Neurology University Hospitals Leuven Leuven Belgium

Department of Neurosciences and Mental Health Hospital Santa Maria CHLN Centro de Estudos Egas Moniz Faculdade de Medicina Universidade de Lisboa Lisbon Portugal

Department of Neurosciences Department of Experimental Neurology and Leuven Research Institute for Neuroscience and Disease KU Leuven University of Leuven Leuven Belgium

Health Research Board Stroke Clinical Trials Network Ireland Dublin Ireland

HRB Clinical Research Facility University of Galway Galway Ireland

Institute for Medical Informatics Biometry and Epidemiology University Hospital University Duisburg Essen Essen Germany

Institute of Psychiatry and Neurology Warsaw Poland

International Clinical Research Center and Department of Neurology St Anne's University Hospital and Masaryk University Brno Brno Czech Republic

Klinikum Main Spessart Lohr Germany

Mater Misericordiae University Hospital Dublin Ireland

Population Health Sciences Institute Newcastle University Newcastle UK

RCSI University of Medicine and Health Sciences and Beaumont Hospital Dublin Ireland

School of Medicine University College Cork Cork Ireland

School of Medicine University College Dublin Dublin Ireland

School of Medicine University of Limerick Limerick Ireland

Stroke Unit Department of Neurology CHC Groupe Santé Liège Belgium

Stroke Unit Department of Neurology Hospitalt Universitari Arnau de Vilanova de Lleida Lleida Spain

TCD Biostatistics Unit Discipline of Public Health and Primary Care School of Medicine Trinity College Dublin Dublin Ireland

University Hospital Monklands Airdrie UK

University Hospital of North Durham Durham UK

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019749
003      
CZ-PrNML
005      
20241024110952.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(24)00968-1 $2 doi
035    __
$a (PubMed)38857611
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kelly, Peter $u Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland; Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland. Electronic address: pjkelly@mater.ie
245    10
$a Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial / $c P. Kelly, R. Lemmens, C. Weimar, C. Walsh, F. Purroy, M. Barber, R. Collins, S. Cronin, A. Czlonkowska, P. Desfontaines, A. De Pauw, NR. Evans, U. Fischer, C. Fonseca, J. Forbes, MD. Hill, D. Jatuzis, J. Kõrv, P. Kraft, C. Kruuse, C. Lynch, D. McCabe, R. Mikulik, S. Murphy, P. Nederkoorn, M. O'Donnell, P. Sandercock, B. Schroeder, G. Shim, K. Tobin, DJ. Williams, C. Price
520    9_
$a BACKGROUND: Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke. METHODS: We did a randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0·5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible. The primary endpoint was a composite of first fatal or non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation (defined as an admission to an inpatient unit or a visit to an emergency department that resulted in at least a 24 h stay [or a change in calendar date if the hospital admission or discharge times were not available]) for unstable angina. The p value for significance was 0·048 to adjust for two prespecified interim analyses conducted by the data monitoring committee, for which the steering committee and trial investigators remained blinded. The trial was registered at ClinicalTrials.gov (NCT02898610) and is completed. FINDINGS: 3154 patients were randomly assigned between Dec 19, 2016, and Nov 21, 2022, with the last follow-up on Jan 31, 2024. The trial finished before the anticipated number of outcomes was accrued (367 outcomes planned) due to budget constraints attributable to the COVID-19 pandemic. Ten patients withdrew consent for analysis of their data, leaving 3144 patients in the intention-to-treat analysis: 1569 (colchicine and usual care) and 1575 (usual care alone). A primary endpoint occurred in 338 patients, 153 (9·8%) of 1569 patients allocated to colchicine and usual care and 185 (11·7%) of 1575 patients allocated to usual care alone (incidence rates 3·32 vs 3·92 per 100 person-years, hazard ratio 0·84; 95% CI 0·68-1·05, p=0·12). Although no between-group difference in C-reactive protein (CRP) was observed at baseline, patients treated with colchicine had lower CRP at 28 days and at 1, 2, and 3 years (p<0·05 for all timepoints). The rates of serious adverse events were similar in both groups. INTERPRETATION: Although no statistically significant benefit was observed on the primary intention-to-treat analysis, the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials. FUNDING: Health Research Board Ireland, Deutsche Forschungsgemeinschaft (German Research Foundation), and Fonds Wetenschappelijk Onderzoek Vlaanderen (Research Foundation Flanders), Belgium.
650    _2
$a senioři $7 D000368
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a kolchicin $x aplikace a dávkování $x terapeutické užití $7 D003078
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a tranzitorní ischemická ataka $x prevence a kontrola $x farmakoterapie $7 D002546
650    12
$a ischemická cévní mozková příhoda $x prevence a kontrola $7 D000083242
650    _2
$a infarkt myokardu $x prevence a kontrola $7 D009203
650    _2
$a recidiva $7 D012008
650    12
$a sekundární prevence $x metody $7 D055502
650    _2
$a cévní mozková příhoda $x prevence a kontrola $7 D020521
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Lemmens, Robin $u Department of Neurology, University Hospitals Leuven, Leuven, Belgium; Department of Neurosciences, Department of Experimental Neurology, and Leuven Research Institute for Neuroscience and Disease (LIND), KU Leuven-University of Leuven, Leuven, Belgium
700    1_
$a Weimar, Christian $u Institute for Medical Informatics, Biometry, and Epidemiology, University Hospital, University Duisburg-Essen, Essen, Germany
700    1_
$a Walsh, Cathal $u TCD Biostatistics Unit, Discipline of Public Health and Primary Care, School of Medicine, Trinity College Dublin, Dublin, Ireland
700    1_
$a Purroy, Francisco $u Stroke Unit, Department of Neurology, Hospitalt Universitari Arnau de Vilanova de Lleida, Lleida, Spain; Biomedical Research Institute of Lleida, Universitat de Lleida, Lleida, Spain
700    1_
$a Barber, Mark $u University Hospital Monklands, Airdrie, UK
700    1_
$a Collins, Ronan $u Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland; Department of Neurology and Department of Geriatric and Stroke Medicine, Tallaght University Hospital-The Adelaide and Meath Hospital, Dublin, Ireland incorporating the National Children's Hospital and Academic Unit of Neurology, School of Medicine, Trinity College Dublin, Dublin, Ireland
700    1_
$a Cronin, Simon $u Cork University Hospital, Cork, Ireland; School of Medicine, University College Cork, Cork, Ireland
700    1_
$a Czlonkowska, Anna $u Institute of Psychiatry and Neurology, Warsaw, Poland
700    1_
$a Desfontaines, Philippe $u Stroke Unit, Department of Neurology, CHC-Groupe Santé, Liège, Belgium
700    1_
$a De Pauw, Adinda $u AZ Oostende, Ostend, Belgium
700    1_
$a Evans, Nicholas Richard $u Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
700    1_
$a Fischer, Urs $u Department of Neurology, University Hospital Bern and University of Bern, Bern, Switzerland
700    1_
$a Fonseca, Catarina $u Department of Neurosciences and Mental Health (Neurology), Hospital Santa Maria-CHLN, Centro de Estudos Egas Moniz, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
700    1_
$a Forbes, John $u Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland; School of Medicine, University of Limerick, Limerick, Ireland
700    1_
$a Hill, Michael D $u Department of Clinical Neurosciences & Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary and Foothills Medical Centre, Calgary, AB, Canada
700    1_
$a Jatuzis, Dalius $u Centre of Neurology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
700    1_
$a Kõrv, Janika $u Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia
700    1_
$a Kraft, Peter $u Klinikum Main-Spessart, Lohr, Germany
700    1_
$a Kruuse, Christina $u Department of Neurology, Herlev and Gentofte Hospital, and Department of Brain and Spinal Cord Injury, Rigshospitalet Hospital, Copenhagen University Hospital, Copenhagen, Denmark
700    1_
$a Lynch, Catherine $u Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland
700    1_
$a McCabe, Dominick $u Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland; Department of Neurology and Department of Geriatric and Stroke Medicine, Tallaght University Hospital-The Adelaide and Meath Hospital, Dublin, Ireland incorporating the National Children's Hospital and Academic Unit of Neurology, School of Medicine, Trinity College Dublin, Dublin, Ireland
700    1_
$a Mikulik, Robert $u International Clinical Research Center and Department of Neurology, St Anne's University Hospital and Masaryk University Brno, Brno, Czech Republic
700    1_
$a Murphy, Sean $u Mater Misericordiae University Hospital, Dublin, Ireland; School of Medicine, University College Dublin, Dublin, Ireland; Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland; RCSI University of Medicine and Health Sciences and Beaumont Hospital, Dublin, Ireland
700    1_
$a Nederkoorn, Paul $u Department of Neurology, Amsterdam University Medical Centers, Amsterdam, Netherlands
700    1_
$a O'Donnell, Martin $u Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland; HRB Clinical Research Facility, University of Galway, Galway, Ireland
700    1_
$a Sandercock, Peter $u Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
700    1_
$a Schroeder, Bernadette $u Center for Clinical Trials Essen, University Hospital Essen, Essen, Germany
700    1_
$a Shim, Gek $u University Hospital of North Durham, Durham, UK
700    1_
$a Tobin, Katrina $u Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland
700    1_
$a Williams, David J $u Health Research Board Stroke Clinical Trials Network Ireland, Dublin, Ireland; RCSI University of Medicine and Health Sciences and Beaumont Hospital, Dublin, Ireland
700    1_
$a Price, Christopher $u Population Health Sciences Institute, Newcastle University, Newcastle, UK
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 404, č. 10448 (2024), s. 125-133
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38857611 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110946 $b ABA008
999    __
$a ok $b bmc $g 2202150 $s 1231722
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 404 $c 10448 $d 125-133 $e 20240607 $i 1474-547X $m Lancet (London, England) $n Lancet $x MED00010161
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...